CD40LG and prostate carcinoma: In patients with T1/T2 stage prostate cancer, there were identified increased IgM anti-GD1a values compared to the T3/T4 stage, which sustains the development of an early endogenous immune response, able to eliminate the danger signal from the tumor microenvironment.